Pharming provides background information on recently completed private offering
Biotech company Pharming Group NV („Pharming“) (NYSE Euronext: PHARM) today announced that it has responded to a letter from the Dutch Association for Private Investors (Vereniging Van Effectenbezitters or „VEB“) to provide additional information to its shareholders on the recently completed offering of new shares.
The VEB is a Dutch organization which represents the interest of private investors. On June 2, 2010, Pharming received a letter from the VEB in which they requested additional information on the recently completed issue of 100 million new Pharming shares, as announced on May 28, 2010. Pharming’s management has responded to these questions on June 9, 2010. Both letters are in Dutch and can be found on the website of the VEB at www.veb.net. The complete list of questions and answers in Dutch and English can be found on Pharming’s website: www.pharming.com > Investor Relations > Public Reports > Equity Fundraising May 2010.
About Pharming Group NV
Pharming Group NV is developing innovative products for the treatment of genetic disorders, ageing diseases, specialty products for surgical indications, and nutritional products. Pharming’s lead product Rhucin® for acute attacks of Hereditary Angioedema has passed clinical development stage and the Market Authorization Application is under review with the European Medicines Agency. Prodarsan® – a product under development by Pharming’s subsidiary DNage – is in early stage clinical development for Cockayne Syndrome and lactoferrin for use in food products. The advanced technologies of the Company include innovative platforms for the production of protein therapeutics, technology and processes for the purification and formulation of these products, as well as technology in the field of DNA repair (via DNage). Recently the partial spin- out of DNage was initiated. Additional information is available on the Pharming website, http://www.pharming.com.
HUG#1423882 by HUGIN